Immune cell therapy for multiple early-stage lung cancers
This trial tests a new immune therapy using your own white blood cells (tumor-infiltrating lymphocytes) to treat non-small-cell lung cancer that has come back or grown. If you have multiple lung spots or your cancer has progressed after surgery or targeted therapy, this study may offer a treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have at least one lung tumor that can be safely sampled (about the size of a grape) to make the treatment.
- You have had non-small-cell lung cancer before, and it has now grown or returned, or you have multiple spots that haven't changed for at least a year.
- Your hemoglobin (iron in blood) level is at least 70 g/L, and organs like your kidneys, liver, and heart are working well.
- You are not currently on steroids, do not have an active serious infection or autoimmune disease, and are not pregnant or planning pregnancy within 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial tests a new treatment for people with non-small cell lung cancer (NSCLC) that was removed by surgery but did not completely disappear after pre-surgery chemoimmunotherapy. The treatment combines your own tumor-fighting cells (L-TIL, grown from your tumor) with an immunotherapy drug (tislelizumab) to try to keep the cancer from coming back.
This trial tests giving tumor-fighting immune cells (TILs) with a targeted therapy pill to people with a specific type of lung cancer (EGFR-mutant NSCLC) that stopped responding to previous targeted treatment. The goal is to see if this combination can shrink or control the cancer again.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
Hear when a new Primary Early-stage Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.